Multipeptide Immune Response to Cancer Vaccine IMA901 After Single-dose Cyclophosphamide Associates with Longer Patient Survival

IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02(+) subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)(+) regulatory T (T(reg)) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of T(reg) cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing.

Citing Articles

Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.

He S, Zheng L, Qi C Mol Cancer. 2025; 24(1):5.

PMID: 39780248 PMC: 11707952. DOI: 10.1186/s12943-024-02208-3.

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

Jung S, Nelde A, Maringer Y, Denk M, Zieschang L, Kammer C Front Oncol. 2024; 14:1458449.

PMID: 39469638 PMC: 11513396. DOI: 10.3389/fonc.2024.1458449.

Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment.

Baharom F, Hermans D, Delamarre L, Seder R Nat Rev Immunol. 2024; 25(3):195-211.

PMID: 39433884 DOI: 10.1038/s41577-024-01091-9.

Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.

Compagno S, Casadio C, Galvani L, Rosellini M, Marchetti A, Tassinari E J Clin Med. 2024; 13(19).

PMID: 39407796 PMC: 11476392. DOI: 10.3390/jcm13195738.

Research progress on prognostic factors of gallbladder carcinoma.

Miao W, Liu F, Guo Y, Zhang R, Wang Y, Xu J J Cancer Res Clin Oncol. 2024; 150(10):447.

PMID: 39369366 PMC: 11456552. DOI: 10.1007/s00432-024-05975-0.

References

Britten C, Meyer R, Kreer T, Drexler I, Wolfel T, Herr W . The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods. 2001; 259(1-2):95-110. DOI: 10.1016/s0022-1759(01)00499-9. View

Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S . Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer. 2009; 125(6):1372-9. DOI: 10.1002/ijc.24497. View

Finke J, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A . Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008; 14(20):6674-82. DOI: 10.1158/1078-0432.CCR-07-5212. View

Wierecky J, Muller M, Wirths S, Halder-Oehler E, Dorfel D, Schmidt S . Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006; 66(11):5910-8. DOI: 10.1158/0008-5472.CAN-05-3905. View

Boss C, Grunebach F, Brauer K, Hantschel M, Mirakaj V, Weinschenk T . Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res. 2007; 13(11):3347-55. DOI: 10.1158/1078-0432.CCR-06-2156. View

Walter S, Bioley G, Buhring H, Koch S, Wernet D, Zippelius A . High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol. 2005; 35(10):2876-85. DOI: 10.1002/eji.200526207. View

Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N . Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep. 2006; 16(1):141-6. View

Burger D, Dayer J . High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation?. Autoimmun Rev. 2003; 1(1-2):111-7. DOI: 10.1016/s1568-9972(01)00018-0. View

Dengjel J, Nastke M, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F . Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res. 2006; 12(14 Pt 1):4163-70. DOI: 10.1158/1078-0432.CCR-05-2470. View

10.

Ruppert J, Sidney J, Celis E, Kubo R, Grey H, Sette A . Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 1993; 74(5):929-37. DOI: 10.1016/0092-8674(93)90472-3. View

11.

Kanagawa N, Niwa M, Hatanaka Y, Tani Y, Nakagawa S, Fujita T . CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int J Cancer. 2007; 121(9):2013-2022. DOI: 10.1002/ijc.22908. View

12.

Atzori L, Mereu R, Satta G, Macis M, Congia M, Tedde A . Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis. 2008; 19(3):218-25. DOI: 10.1016/j.numecd.2008.06.002. View

13.

Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View

14.

Schuster S, Neelapu S, Gause B, Janik J, Muggia F, Gockerman J . Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011; 29(20):2787-94. PMC: 3139394. DOI: 10.1200/JCO.2010.33.3005. View

15.

Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J . Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007; 178(11):6730-3. DOI: 10.4049/jimmunol.178.11.6730. View

16.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

17.

Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A . Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203(7):1693-700. PMC: 2118333. DOI: 10.1084/jem.20060468. View

18.

Chianese-Bullock K, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G . MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005; 174(5):3080-6. DOI: 10.4049/jimmunol.174.5.3080. View

19.

Singh-Jasuja H, Emmerich N, Rammensee H . The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother. 2004; 53(3):187-95. PMC: 11032959. DOI: 10.1007/s00262-003-0480-x. View

20.

Schwartzentruber D, Lawson D, Richards J, Conry R, Miller D, Treisman J . gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364(22):2119-27. PMC: 3517182. DOI: 10.1056/NEJMoa1012863. View